Distinguishing the Concentration- vs. Bioaccumulation-Dependent Immunological and Metabolic Effects of Clofazimine
The antimycobacterial drug clofazimine (CFZ) is used as a single agent at high doses, to suppress the exaggerated inflammation associated with leprosy. Paradoxically, increasing doses of CFZ leads to bioaccumulation of CFZ in the spleen and other organs under physiologically relevant dosing regimens...
Saved in:
Main Authors: | Andrew R. Willmer (Author), Jennifer Diaz-Espinosa (Author), Austin Zhou (Author), Kathleen A. Stringer (Author), Gus R. Rosania (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of Clofazimine
by: Andrew R. Willmer, et al.
Published: (2021) -
Synthesis and Characterization of a Biomimetic Formulation of Clofazimine Hydrochloride Microcrystals for Parenteral Administration
by: Mikhail D. Murashov, et al.
Published: (2018) -
Investigation of Bioaccumulation of Heavy Metals Concentration in Arak Metropolitan
by: Mina Taghizadeh, et al.
Published: (2019) -
Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota
by: Laura E. McCoubrey, et al.
Published: (2021) -
Clofazimine for the treatment of tuberculosis
by: Jacob A. M. Stadler, et al.
Published: (2023)